These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8139735)

  • 21. Clinical pharmacokinetics and dose optimisation of carboplatin.
    Duffull SB; Robinson BA
    Clin Pharmacokinet; 1997 Sep; 33(3):161-83. PubMed ID: 9314610
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
    Warren K; Gervais A; Aikin A; Egorin M; Balis FM
    Cancer Chemother Pharmacol; 2004 Sep; 54(3):206-12. PubMed ID: 15156345
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Appropriate hemodialysis scheduling based on therapeutic drug monitoring of carboplatin in a patient with lung cancer and chronic renal failure].
    Kamata H; Asano K; Soejima K; Shirahata T; Nakatani M; Inamoto H; Iketani O; Yamayoshi Y; Tanigawara Y; Ishizaka A
    Gan To Kagaku Ryoho; 2009 Sep; 36(9):1529-32. PubMed ID: 19755826
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic analysis of carboplatin and etoposide in a small cell lung cancer patient undergoing hemodialysis.
    Takezawa K; Okamoto I; Fukuoka M; Nakagawa K
    J Thorac Oncol; 2008 Sep; 3(9):1073-5. PubMed ID: 18758316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of combination chemotherapy with paclitaxel and carboplatin in a patient with advanced epithelial ovarian cancer undergoing hemodialysis.
    Kodama J; Sasaki A; Masahiro S; Seki N; Kusumoto T; Nakamura K; Hongo A; Hiramatsu Y
    Oncol Lett; 2010 May; 1(3):511-513. PubMed ID: 22966334
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.
    Huizing MT; van Warmerdam LJ; Rosing H; Schaefers MC; Lai A; Helmerhorst TJ; Veenhof CH; Birkhofer MJ; Rodenhuis S; Beijnen JH; ten Bokkel Huinink WW
    J Clin Oncol; 1997 May; 15(5):1953-64. PubMed ID: 9164207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic analyses of carboplatin in a patient with cancer of the fallopian tubes undergoing hemodialysis: A case report.
    Wada T; Fukuda T; Kawanishi M; Tasaka R; Imai K; Yamauchi M; Kasai M; Hashiguchi Y; Ichimura T; Yasui T; Sumi T
    Biomed Rep; 2016 Aug; 5(2):199-202. PubMed ID: 27446541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The pharmacokinetics of intraperitoneal (IP) carboplatin (CBDCA) and dose-up study of intravenous (IV) cyclophosphamide (CPM) in combination with IP CBCDA for advanced ovarian cancer patients].
    Fujiwara K; Yamauchi H; Sawada S; Koike H; Mohri H; Ohishi Y; Kohno I
    Gan To Kagaku Ryoho; 1992 Dec; 19(14):2373-9. PubMed ID: 1463344
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer.
    Reyno LM; Egorin MJ; Canetta RM; Jodrell DI; Swenerton KD; Pater JL; Burroughs JN; Novak MJ; Sridhara R
    J Clin Oncol; 1993 Jun; 11(6):1156-64. PubMed ID: 8501502
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of carboplatin in a patient with cervical cancer with ureteric obstruction before, during, and after hemodialysis.
    el-Yazigi A; Alfurayh O; Amer M
    J Clin Pharmacol; 1995 Oct; 35(10):1003-7. PubMed ID: 8568007
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical pharmacokinetics of carboplatin.
    van der Vijgh WJ
    Clin Pharmacokinet; 1991 Oct; 21(4):242-61. PubMed ID: 1760899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dose adjustment of carboplatin in patients on peritoneal dialysis.
    Guddati AK; Joy PS; Marak CP
    Med Oncol; 2014 May; 31(5):946. PubMed ID: 24706216
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extension of the Calvert formula to patients with severe renal insufficiency.
    Oguri T; Shimokata T; Ito I; Yasuda Y; Sassa N; Nishiyama M; Hamada A; Hasegawa Y; Ando Y
    Cancer Chemother Pharmacol; 2015 Jul; 76(1):53-9. PubMed ID: 25957958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.
    Katsumata N; Yasuda M; Takahashi F; Isonishi S; Jobo T; Aoki D; Tsuda H; Sugiyama T; Kodama S; Kimura E; Ochiai K; Noda K;
    Lancet; 2009 Oct; 374(9698):1331-8. PubMed ID: 19767092
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose adjustment of carboplatin in patients on hemodialysis.
    Guddati AK; Joy PS; Marak CP
    Med Oncol; 2014 Mar; 31(3):848. PubMed ID: 24452283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I trial of intravenous carboplatin and cyclosporin A in refractory gynecologic cancer patients.
    Chambers SK; Davis CA; Chambers JT; Schwartz PE; Lorber MI; Hschumacher RE
    Clin Cancer Res; 1996 Oct; 2(10):1699-704. PubMed ID: 9816119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support.
    Margolin K; Doroshow JH; Ahn C; Hamasaki V; Leong L; Morgan R; Raschko J; Shibata S; Somlo G; Tetef M
    J Clin Oncol; 1996 Oct; 14(10):2631-7. PubMed ID: 8874321
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of mesna on the pharmacokinetics of cisplatin and carboplatin in pediatric cancer patients.
    Kangarloo SB; Gangopadhyay SB; Syme RM; Wolff JE; Glück S
    Med Oncol; 2004; 21(1):9-20. PubMed ID: 15034209
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin--a Sankai Gynecology Study Group (SGSG) study.
    Miyagi Y; Fujiwara K; Kigawa J; Itamochi H; Nagao S; Aotani E; Terakawa N; Kohno I;
    Gynecol Oncol; 2005 Dec; 99(3):591-6. PubMed ID: 16095677
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population pharmacokinetic and limited sampling models for carboplatin administered in high-dose combination regimens with peripheral blood stem cell support.
    Shen M; Schilder RJ; Obasaju C; Gallo JM
    Cancer Chemother Pharmacol; 2002 Sep; 50(3):243-50. PubMed ID: 12203107
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.